Cystic Neoplasms of the Pancreas: Diagnosis and Management

Cystic neoplasms of the pancreas encompass a heterogeneous group of lesions ranging from benign entities to precursors of invasive carcinoma. Key subtypes include serous cystic neoplasms, mucinous cystic neoplasms and intraductal papillary mucinous neoplasms (IPMNs). Accurate characterisation of these lesions is vital to balance the risks of overtreatment against the potential for malignant transformation. Current diagnostic pathways integrate cross-sectional imaging, endoscopic ultrasound with cyst fluid sampling, and surgical assessment when indicated. Risk stratification relies on morphological criteria—such as cyst size, mural nodules and ductal dilation—alongside biochemical and cytological analysis of cyst fluid. Management algorithms distinguish candidates for surveillance from those requiring resection, guided by international consensus guidelines. Despite these advances, diagnostic uncertainty persists, driving research into molecular profiling, quantitative imaging biomarkers and machine-learning approaches. Improved understanding of clonal evolution, combined with novel fluid and imaging-derived biomarkers, promises to refine early detection and individualise treatment decisions, thereby reducing morbidity and improving long-term outcomes worldwide.

Research from Nature Portfolio

Recent studies have employed spatial transcriptomics to delineate gene expression patterns across IPMN subtypes, identifying discrete molecular markers associated with low-grade, borderline and high-grade dysplasia. This work has revealed activation of TNFα and MYC pathways and subtype-specific transcription factors such as HOXB3, ZNF117 and NKX6-2 that correlate with malignant progression. Complementary genomic analyses of neoplastic cysts have confirmed that both IPMNs and mucinous cystic neoplasms serve as direct precursors to pancreatic cancer. Whole-exome and targeted sequencing efforts mapped clonal dynamics over a three-year window between high-grade dysplasia and invasive carcinoma, highlighting RNF43 alterations in non-invasive lesions and SMAD4 and TGFBR2 mutations in invasive foci. These findings underscore a potential interventional window and pinpoint candidate drivers for targeted surveillance and therapeutic intervention.

Cystic Neoplasms of the Pancreas: Diagnosis and Management publication trend

The graph below shows the total number of articles in cystic neoplasms of the pancreas: diagnosis and management across all publications each year (not limited to Nature Index journals).

Technical terms

Intraductal Papillary Mucinous Neoplasm (IPMN): A mucin‐producing cystic lesion arising from the pancreatic ducts, with variable risk of progression to carcinoma.

Mucinous Cystic Neoplasm (MCN): A cystic tumour lined by mucinous epithelium, typically containing ovarian‐type stroma and carrying malignant potential.

Spatial Transcriptomics: A technology that maps gene expression to precise tissue locations, revealing spatial heterogeneity within lesions.

Radiomics: Quantitative extraction of imaging features—such as texture and shape—from medical scans, used for predictive modelling.

Glycoproteomics: A branch of proteomics focused on the identification and analysis of protein glycosylation patterns as biomarkers.

High-Grade Dysplasia: A premalignant state in which epithelial cells exhibit significant architectural and cytological atypia but remain non-invasive.

References

1. Identification of spatially-resolved markers of malignant transformation in Intraductal Papillary Mucinous Neoplasms. Nature Communications (2024).
2. Genomic characterization of malignant progression in neoplastic pancreatic cysts. Nature Communications (2020).
3. Cyst fluid glycoproteins accurately distinguishing malignancies of pancreatic cystic neoplasm. Signal Transduction and Targeted Therapy (2023).
4. Machine Learning‐Based Radiomics in Malignancy Prediction of Pancreatic Cystic Lesions: Evidence from Cyst Fluid Multi‐Omics. Advanced Science (2025).